Systematic analyses of a novel lncRNA‐associated signature as the prognostic biomarker for Hepatocellular Carcinoma

Abstract

Accumulating evidence implies that long noncoding RNAs (lncRNAs) play a crucial role in predicting survival for Hepatocellular carcinoma (HCC) patients. This study aims to capture the current research hotspots of HCC, based on the analysis of publications related to HCC research from 2013 to 2017, and to identify a novel lncRNA signature for HCC prognosis through the data mining in The Cancer Genome Atlas (TCGA). “Prognosis” and “biomarker” were located in the core of the HCC research hotspot. Moreover, long noncoding RNA was the top one research frontier in HCC research. The associations between survival outcome and the expression of lncRNAs were evaluated by the univariate and multivariate Cox proportional hazards regression analyses. Four lncRNAs (LINC00261, TRELM3P, GBP1P1, and CDKN2B‐AS1) were identified as significantly correlated with overall survival (OS). These four lncRNAs were gathered as a single prognostic signature. There was a significant positive correlation between HCC patients with low‐risk scores and overall survival (HR = 1.802, 95%CI [1.224‐2.652], P = .003). Further analysis suggested that the prognostic value of this four‐lncRNA signature was independent in clinical features. The enrichment analysis of prognostic lncRNA‐related gene was performed to find out the related pathways. Our study indicates that this novel lncRNA expression signature may be a useful biomarker of the prognosis for HCC patients, based on bioinformatics analysis.

Risk scoring based on expression of long non‑coding RNAs can effectively predict survival in hepatocellular carcinoma patients with or without fibrosis

“…Several previous studies have also constructed risk scoring systems to predict the prognosis of patients with HCC (24)(25)(26)(27)(28)(29)(30)(31). However, those risk scoring systems were based on DElncRNAs between HCC and normal samples, while the risk scoring systems in the present study are based on the DElncRNAs between HCC Table IX.…”

LncRNAs in HCV Infection and HCV-Related Liver Disease

“…Interestingly, it has been shown that most lncRNAs deregulated in cancer are tumor-specific, whereas only a handful behave as "onco-lncRNAs", deregulated across many cancer types [54,60,61]. This has encouraged the development of a whole new field for the exploration of lncRNAs in cancer as a source of novel molecular targets and as biomarkers for diagnosis [62], predictors of treatment response [63], disease-free and overall survival [64,65] and risk of metastasis [66]. Similarly, deregulation and functional implications of lncRNAs have been studied in many other diseases, including HCV infection.…”

Integrating the lncRNA and mRNA expression profiles of TLR4-primed mesenchymal stem cells in ankylosing spondylitis

“…In this study, several lncRNAs with the largest fold changes among DE lncRNAs were studied. For example, GBP1P1 is a lncRNA that acts as a prognostic biomarker for hepatocellular carcinoma [32]. MIR3142HG can regulate the in ammatory response following IL-1β-mediated activation of human lung broblasts, which is a positive regulator of IL-8 and CCL2 release [33].…”